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This document presents the summary findings from the
34th Bethesda Conference: “Can Atherosclerosis Imaging
Techniques Improve the Detection of Patients at Risk for
Ischemic Heart Disease?” This conference, comprised of
five writing groups, began the process of formulating report
outlines and documents in January 2002. The conference,
held October 7, 2002, at the Heart House in Bethesda,
Maryland, allowed for open discussion, constructive com-
mentary, and the formulation of summary comments result-
ing in the documents presented in this report. The purpose
of Bethesda Conference 34 (BC 34) was to review the
current status and controversies within the integration of
atherosclerosis imaging into clinical cardiovascular medi-
cine. Each Task Force was also specifically charged with
developing recommendations on “Future Directions” for the
field of atherosclerosis imaging, as appropriate within the
scope of issues they considered.
Although it is recognized that atherosclerosis imaging,
including many different emerging technologies, may en-
hance the detection and treatment of patients at risk for
coronary heart disease (CHD), much remains unknown
about these modalities despite the fact that many are rapidly
moving into broad clinical use. Further consideration of
these tests as clinical tools extends prior efforts such as the
Prevention V Conference of the American Heart Associa-
tion, and the National Cholesterol Education Program,
Adult Treatment Panel III guidelines. The latter treatment
guidelines focused particular attention on the relevance of
diagnosing subclinical atherosclerosis for altering lipid treat-
ment goals by designating that aortic, peripheral, and
carotid artery disease were considered to represent “Coro-
nary Heart Disease Equivalents” because the level of CHD
risk and CHD event rates associated with these conditions
is approximately equivalent to the level of risk seen in stable
CHD. Thus, screening for atherosclerosis in other vascular
regions has been considered for CHD risk evaluation.
The BC 34 brought together the multidisciplinary exper-
tise of pathologists, epidemiologists, imaging experts, ex-
perts in disease detection and treatment, clinical trialists,
and outcomes researchers to work together for the common
goal of crystallizing the current science, addressing the many
unanswered questions on the appropriate clinical use of the
available imaging modalities, and envisioning the future of
this discipline. For the purpose of this Bethesda Confer-
ence, we adhered to the use of the term “coronary heart
disease” (CHD) defined as cardiac events or symptoms
related to myocardial ischemia and/or injury due, in the vast
majority of cases, to atherosclerosis. Such events include
unstable angina, myocardial infarction (MI), and sudden
death due to ischemic heart disease. It is important to
recognize that coronary atherosclerosis, ischemia, and
events exist as a continuum. The former need not necessarily
lead to the latter, while the latter is virtually always preceded
by the presence of the former. Thus, the challenge is not only
to “detect” coronary atherosclerosis, but also to “predict”
which individuals, in whom coronary atherosclerosis is
detected, will progress to develop events. Finally, the use of
global risk scores, such as the Framingham Risk Score, was
considered as the most appropriate initial assessment of all
patients undergoing coronary risk screening. Additional
testing, such as imaging, must provide incremental risk-
prediction information to the Framingham Risk Score. A
modification to this subgrouping has recently been sug-
gested to improve CHD risk assessment in asymptomatic
people. This approach considers a less than 0.6% per year
(less than 6% over 10 years) risk for coronary events as
“low-risk,” 0.6% to 2.0% per year (6% to 20% over 10 years)
risk is termed “intermediate risk,” and individuals with
greater than or equal to 2.0% per year (greater than or equal
to 20% over 10 years) risk are “high-risk.” We have adopted
these risk groupings for this Bethesda Conference.
TASK FORCE 1: IDENTIFICATION OF CORONARY
HEART DISEASE RISK: IS THERE A DETECTION GAP?
Task Force 1 addressed the rationale for new methods to
detect cardiovascular risk based upon limitations of current
clinical screening methods within the context of primary
CHD prevention. Current CHD risk-screening tools are
imperfect and imperfectly applied, thus potential opportu-
nities exist with atherosclerosis imaging for CHD risk
assessment refinement. The “detection gap” may be defined
as the difference between CHD cases or events currently
detected and the total burden of disease or events among the
population. Whether this gap may be due to current testing
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not optimally detecting disease, or due to testing not being
appropriately applied, is incompletely understood. Although
agreed that a detection gap in CHD prognosis exists, the
precise size of this gap, and thus the potential for athero-
sclerosis imaging to reduce cardiovascular morbidity and
mortality through enhanced risk screening, is unknown, but
may be substantial. The application of atherosclerosis im-
aging to intermediate-risk populations is theoretically “op-
timal” based upon the Bayes’ theorem. This assumption,
and the potential extension of these tests to both low- and
high-risk populations, is in need of a greater body of
supporting evidence in which incremental management and
prognostic impact is demonstrated. Proper calibration of the
results of atherosclerosis imaging modalities is necessary to
avoid systematic under- or overdetection of patients as being
at heightened CHD risk.
In concert with efforts to improve the accuracy of office-
based CHD risk detection, a need exists for more wide-
spread clinical use of CHD risk-scoring algorithms. Recog-
nition of such efforts as valid and valuable clinical
assessments in the form of specific reimbursement codes
would further the penetrance of these tools into clinical
practice. The community of cardiologists must champion
CHD prevention, beginning by fully translating existing
data on effective risk interventions into practice.
TASK FORCE 2: WHAT IS THE PATHOLOGIC BASIS
FOR NEW ATHEROSCLEROSIS IMAGING TECHNIQUES?
Task Force 2 addressed the anatomic targets within athero-
sclerosis that form the basis for imaging modalities, includ-
ing the relationship between plaque burden and the pathol-
ogy of vulnerable atherosclerosis. Plaque burden is generally
substantial in the majority of patients with acute coronary
events. Ultimately, imaging individual plaque components
might achieve importance in detecting both lesions and
individual patients prone to plaque rupture. However, an
incremental value for imaging atherosclerotic components
(above and beyond assessing plaque burden) in predicting
acute coronary events requires validation. A particularly rich
area for exploration of vulnerable plaque detection is in
younger individuals who often have relatively little plaque
burden. In the future, the development of a “vulnerable
plaque scoring system” could be feasible, including the
characteristics of: 1) fibrous-cap thickness, 2) necrotic core
size (both percent of cross-sectional plaque area and length),
3) degree of macrophage infiltration, and 4) compensatory
remodeling. In comparison, coronary calcification princi-
pally reflects overall plaque burden, although it has pathol-
ogy relationships to healed plaque ruptures and compensa-
tory remodeling. Thus, indirectly, calcium measurements
may reflect underlying plaque biology and propensity for
future plaque rupture events.
TASK FORCE 3: WHAT IS THE
SPECTRUM OF CURRENT AND
EMERGING TECHNIQUES FOR THE
NONINVASIVE MEASUREMENT OF ATHEROSCLEROSIS?
Task Force 3 reviewed the existing and emerging noninva-
sive technologies for atherosclerosis imaging. The imaging
modalities considered within the document include carotid
ultrasound for assessment of intima-media thickness
(IMT), coronary calcium scanning, cardiovascular magnetic
resonance imaging (CMR) for atherosclerosis, brachial ar-
tery reactivity testing, and the ankle-brachial index (ABI).
Development of atherosclerosis imaging tests must be
viewed as a continuum from device validation, diagnostic
accuracy, prognostic accuracy, to demonstrating an inde-
pendent and incremental impact on CHD risk management
and CHD outcomes. The currently available atherosclerosis
imaging modalities are in different phases of development.
The modalities vary greatly in important parameters such as
their availability, their reproducibility, and their costs. In
general, the available data (although no data are available for
CMR) indicate that abnormal values on atherosclerosis
imaging have been associated with a three-fold or greater
risk of a future CHD event. Although the supporting data
for ABI and IMT most clearly show an independent
prognostic impact of the test results, these technologies are
also most static, with little room for further technical
development. None of the available tests have yet been
demonstrated to impact CHD management or outcomes.
The diagnostic and prognostic effectiveness of more mature
modalities as CHD risk screening tools cannot be general-
ized to newer modalities (e.g., plaque burden testing with
CMR must be independently validated for CHD progno-
sis). Among all modalities, a need exists to move toward
broader standardization of imaging modalities to ensure
external validity of published reports, and enable cross-study
comparisons. Because atherosclerosis imaging test results
can be considered continuous, improved definition of “pos-
itive” versus “negative” results is warranted. There is a need
for cross-modality prospective comparisons recognizing
that, among important subgroups (e.g., gender and race),
modalities may perform differently in detecting CHD prog-
nosis.
TASK FORCE 4: HOW DO WE SELECT
PATIENTS FOR ATHEROSCLEROSIS IMAGING?
Task Force 4 addressed the application of atherosclerosis
imaging tests to patients, including the selection of patients
within categories of clinically predicted heart disease risk,
matching patients to specific imaging modalities, and man-
agement of the results. A valuable screening test should: a)
identify both high- and low-risk groups (e.g., a low propor-
tion of false negative and false positives) more accurately; b)
enhance the identification of high-risk individuals, c) result
in a favorable impact on disease outcomes; d) be relatively
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free of risk; e) be cost-effective when compared to the
current screening modalities; and f) educate the public
concerning atherosclerosis and vascular disease risk. Select-
ing intermediate-risk patients for screening with plaque-
burden assessment has potential theoretical advantages
within a Bayesian approach to screening. More study is
needed in low- and high-risk patients. Once a modality is
shown to incrementally and to a clinically important extent
predict cardiovascular risk, then effectiveness studies are
appropriate to establish threshold values (indicating a shift
to increased intensity of risk-factor treatments) and to
determine their impact on management and CHD out-
comes. Until such effectiveness studies are complete, the
appropriateness of shifting individual patients to more
intense risk-reduction therapies based on atherosclerosis
imaging modalities requires clinical judgment.
Limitations of modalities within specific patient popula-
tions are beginning to emerge. Currently, coronary calcium
detection and the ABI, abnormal primarily in the setting of
advanced atherosclerosis, have limited application to young
patients. A specific ethnic-based imaging limitation appears
to be present for coronary calcium, particularly in African-
Americans. The outcome of efforts to better detect CHD
risk is ultimately dependent upon the effectiveness of the
risk-reduction therapies that ensue. A policy of self-referral
to atherosclerosis imaging tests remains premature and
should be the subject of formal effectiveness study prior to
widespread adoption of this practice.
TASK FORCE 5:
IS ATHEROSCLEROSIS IMAGING COST-EFFECTIVE?
Task Force 5 addressed the role of cost-effectiveness con-
siderations in atherosclerosis imaging. Cost-effectiveness
data are increasingly being applied to the evaluation of
imaging technology, and optimally it should be considered
in parallel with the development of imaging modalities. The
aim of cost-effectiveness analysis is to guide health care
payers and regulators in the evaluation of new therapies and
technology for the setting of standards for use, reimburse-
ment, and for approving use. A requisite amount of high-
quality clinical effectiveness data is necessary for the deter-
mination of an added economic benefit. Thus, an important
need exists for high-quality, long-term outcome data to be
developed for all of the newer imaging modalities so as to
inform potential models of cost-effectiveness. Standards for
defining cost-effectiveness include the amount of resources
or costs required to achieve a given clinical benefit. Such
standards, developed from therapeutic intervention data and
models, may not be directly applicable to the use and
application of imaging modalities to detect subclinical
atherosclerosis. As such, professional societies and stake-
holder government agencies as well as senior leaders in
health care economic analysis should convene to create and
define standards for evaluating imaging procedures with
regard to costs and outcomes. Current clinical and economic
effectiveness analysis are hampered by a lack of clinical
algorithms with noted inputs for serial testing, post-test
treatment strategies, resultant proportional risk reduction,
as well as induced resource consumption levels with a variety
of atherosclerosis imaging modalities. Future research in the
area of atherosclerosis imaging must provide more definitive
data regarding the links between the initial imaging proce-
dure and results and subsequent downstream testing and
treatment effectiveness. Substantial additional data are
needed for virtually all currently available and developing
modalities of atherosclerosis imaging prior to the support of
any techniques being considered as cost-effective.
CALL FOR CLINICAL TRIALS
Observational data are key to improving management of
cardiovascular disease, but diagnostic imaging utility should
also be tested with randomized clinical trials. Undertaking
an experimental design, including blinding the involved
patients and their physicians, would allow rigorous testing
of the utility of the new procedures. Appropriate exclusion
criteria within such an experimental design would be nec-
essary to address concerns over withholding information for
individuals with very “abnormal” test results. Alternatively,
rigorous analysis of testing strategies in this situation might
be undertaken by randomizing patients to testing or no
testing, then prospectively assessing outcomes. Important
design elements include demonstrating incremental diag-
nostic and management impact beyond that achieved with
global risk scoring algorithms, and inclusion of emerging
markers of CHD risk. Such studies would also serve the
valuable purpose of determining appropriate thresholds for
the results of atherosclerosis imaging and providing input
data for cost-effectiveness models.
Finally, an important concept worthy of testing is the
value of a “negative” test—for example, toward reducing the
post-test probability of disease and validating therapeutic
avoidance. As with all clinical trials, both the presence and
magnitude of clinically relevant results are important inter-
pretive considerations. Funding support for such initiatives
from both the private and public sector is strongly encour-
aged.
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